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AbstrAct
Parkinson’s disease (PD) is a disorder characterized by the degeneration of 
certain neuronal populations in the central and peripheral nervous system. One of 
the hallmarks of the disease is the toxic accumulation of proteins within susceptible 
neurons due to major impairment in the d  egradation/clearance protein systems. 
RTP801 is a pro-apoptotic protein that is sufficient and necessary to induce 
neuronal death in cellular and animal models of PD. RTP801 is also upregulated in 
sporadic and parkin mutant PD brains. Here, we report the role of NEDD4, an E3 ligase 
involved in α-synuclein degradation and PD pathogenesis, in the regulation of RTP801 
protein levels and toxicity. NEDD4 polyubiquitinates RTP801 in a cell-free system and 
in cellular cultures, and they interact physically. NEDD4 conjugates K63-ubiquitin 
chains to RTP801 and targets it for degradation. NEDD4 regulates RTP801 protein 
levels in both cultured cells and in the brain tissue. NEDD4 levels are diminished in 
nigral neurons from human PD brains. Interestingly, neurotoxin 6-OHDA decreases 
dramatically NEDD4 protein expression but elevates RTP801 protein levels. Moreover, 
NEDD4 protects neuronal PC12 cells from both 6-OHDA and RTP801-induced toxicity. 
In primary cortical neurons, NEDD4 knockdown toxicity is mediated by RTP801 since 
the double knockdown of RTP801 and NEDD4 abrogates the loss of phospho Ser473-
Akt and the appearance of caspase-cleaved spectrin fragments. 
Thus, NEDD4 ligase regulates RTP801 and is sensitive to PD-associated oxidative 
stress. This suggests that NEDD4 loss of function in PD could contribute importantly 
into neuronal death by elevating RTP801.
INtrODUctION
In Parkinson’s disease (PD), the mechanisms 
by which specific subpopulations of both central and 
peripheral neurons degenerate are not yet elucidated [1]. 
Moreover, only palliative treatments exist to ameliorate 
the clinical manifestations of the disease but they do not 
prevent neuron degeneration and death [2-4]. 
RTP801 is a stress-regulated protein with several 
functions depending on the cellular context [5]. In a 
variety of neuronal systems, RTP801 overexpression is 
sufficient to trigger cell death [5, 6]. In cellular models of 
PD, shRNA-mediated RTP801 knockdown is protective 
toward cell death induced by 6-hydroxydopamine (6-
OHDA) or MPP+ [6]. Consistently, RTP801 is required 
for cell death triggered by MPP+/MPTP in in vivo model 
of PD [6]. 
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RTP801 triggers neuron cell death by a sequential 
mechanism in which it first inactivates mechanistic target 
of Rapamycin (mTOR) and then, as a consequence, 
inhibits the neuronal survival kinase Akt, which is also 
a substrate of mTOR [6, 7]. In human postmortem 
tissue, RTP801 was found to be highly upregulated 
in neuromelanin (NM) positive neurons in the SNpc 
of both sporadic [6] and parkin mutant PD patients [8] 
in comparison with control non-PD brains. Also, in 
accordance with the mechanism proposed from our in vitro 
studies, very low levels of phospho-Akt (both Serine 473 
and Threonine 308) were observed in nigral PD neurons 
in comparison to non-PD brains [7].
One remarkable feature of RTP801 protein is its 
very short half-life (2-5 min) [9, 10], suggesting that 
its synthesis and degradation are regulated strictly and 
dynamically. Our previous study demonstrated that parkin, 
a RING E3 ligase, ubiquitinates RTP801 and targets it for 
ubiquitin proteasome system (UPS) [8]. 
Neural precursor cell expressed, developmentally 
down-regulated 4 (NEDD4) is one of the most abundant 
ubiquitin E3 ligases in mammalian neurons [11]. NEDD4 
ubiquitinates proteins, targeting them for proteasomal 
or lysosomal degradation [12]. In developing neurons, 
NEDD4 plays crucial roles in axon growth and dendrite 
sprouting [13, 14]. In a context of PD, NEDD4 protects 
neurons from alpha synuclein toxicity by ubiquitinating 
it and mediating its lysosomal degradation [15, 16]. 
Interestingly, NEDD4 staining is very strong in nigral 
neurons containing Lewy bodies (LB) in the human 
Substantia Nigra (SN) and the Locus Coeruleus (LC) from 
patients with LB pathologies [15]. Furthermore, NEDD4 
presents a single nucleotide polymorphism (SNP) that has 
been associated with a major risk factor for sporadic PD in 
a whole genome association study (GWAS) [17].
Here, we identify NEDD4 as a novel E3 ubiquitin 
ligase for RTP801, controlling its homeostasis. 
Importantly, NEDD4 is downregulated in remaining 
nigral neurons from PD brains. Moreover, 6-OHDA 
downregulates NEDD4 in neural cultures and NEDD4 
deregulation contributes to toxic elevation of RTP801 in 
cellular models of PD.
rEsULts
rtP801 is degraded by the lysosomal pathway 
and polyubiquitinated by NEDD4
In our previous work we showed that RTP801 
has a very short half-life and is mostly degraded by 
the proteasome [8-10]. Hence, we first asked whether 
lysosomal pathway could contribute to RTP801 
protein degradation. As cellular models we used NGF-
differentiated PC12 cells, a cell line that resembles 
sympathetic neuroblasts which is a neuronal population 
also affected in PD [3, 18], and rat primary cortical 
neurons, that are also sensitive to 6-OHDA [19] or alpha-
synuclein toxicity [20]. We first exposed the cultures 
to chloroquine, a lysosomotropic agent that prevents 
endosomal acidification and thus inhibits lysosomal fusion 
and protein degradation [21, 22]. Sister cultures were 
treated with proteasome inhibitors epoxomicin or MG132. 
Western immunoblotting (WB) showed that RTP801 
was accumulated upon the inhibition of the proteasome, 
as previously described [8]. Interestingly, chloroquine 
induced a significant elevation of RTP801 after 4-hour 
exposure in both cultured cell types (Figure 1a). 
Given that ubiquitination is involved in lysosomal 
degradation [23], we next investigated which E3 ligase 
could mediate lysosomal degradation of RTP801. We 
investigated NEDD4, which is an E3 ligase involved in 
PD by regulating alpha-synuclein proteostasis. Hence, we 
assessed whether recombinant NEDD4 polyubiquitinated 
RTP801 in a cell free assay. For this purpose, we incubated 
recombinant NEDD4, recombinant GST-RTP801, 
biotinylated Ubiquitin, an E1 ubiquitin-activating enzyme, 
and UbcH5b at 37ºC for 90 min. After incubation, RTP801 
was immunoprecipitated and analyzed by WB. By using 
an anti-biotin antibody, we observed the appearance of 
high molecular weight ubiquitinated RTP801 (HMW-Ub 
RTP801) species when all the enzymes and the substrates 
were present in the reaction (Figure 1b). Hence, NEDD4 is 
able to directly ubiquitinate RTP801 in a cell-free system.
To explore whether this process takes place in a 
cellular model, wild type (WT) NEDD4, RTP801, and 
Hemagglutinin (HA)-tagged ubiquitin (HA-Ub) were 
overexpressed in HEK293 cells. Two days later, cells 
were harvested and RTP801 was immunoprecipitated. WB 
analysis of the immunocomplexes showed that ectopic 
NEDD4 significantly increased the appearance of HMW-
Ub RTP801 with different lengths of polyubiquitin chains 
(Figure 1c). These results suggest that NEDD4 enhances 
polyubiquitination of RTP801 in cellular cultures.
To investigate which kind of ubiquitin chains 
NEDD4 uses preferentially with RTP801, we transfected 
HEK293 cells with expression vectors for pCMS-eGFP-
RTP801, NEDD4, and modified HA-Ubiquitin. The 
ubiquitin plasmids have all the lysine residues mutated 
to arginine except for 48th or 63rd lysine residue (K48 or 
K63). This preferentially leads to the formation of K48- 
or K63-linked polyubiquitin chains at the substrates. WB 
analysis of RTP801 immunoprecipitates showed that the 
RTP801 HMW smear was increased only in the presence 
of overexpressed NEDD4 along with HA-Ub-K63. Thus, 
NEDD4 polyubiquitinates RTP801 preferentially with 
K63-linked polyubiquitin chains (Figure 1d). Note that 
with HA-Ub-K48, the appearance of RTP801 HMW smear 
is independent of ectopic NEDD4. This indicates that 
RTP801 is ubiquitinated with K48 chains by other ligases, 
like parkin, and degraded by the proteasome [8]. 
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Figure 1: rtP801 is polyubiquitinated by NEDD4 and degraded by the lysosomal pathway. a. RTP801 can be degraded 
by both the ubiquitin proteasome system and by the lysosomal pathway. NGF-differentiated PC12 cells or cortical neurons were treated 
during 4 hours with 1 µM epoxomycin, 10 µM MG132 or 50 µM chloroquine, and cell lysates were subjected to Western Blot. Membranes 
were probed first for RTP801 and then with α-actin, as a loading control. All samples were immunoblotted in the same membrane, but 
one irrelevant lane was deleted in the second panel. Graphs represent densitometric values (mean ± SEM) normalized to α-actin of three 
independent experiments in triplicates. Student’s t-test, ***P < 0.001 and *P < 0.05 versus controls. b. NEDD4 polyubiquitinates RTP801 
in a cell free assay. Recombinant NEDD4 E3 ligase, recombinant GST-RTP801, UbcH5b E2 enzyme, E1 enzyme, biotinylated ubiquitin and 
ATP were mixed and incubated at 37ºC for 90 min. RTP801 was immunoprecipitated and immunocomplexes were analyzed by Western Blot. 
The membrane was incubated with Avidin/Biotin and then with chemiluminiscent peroxidase substrate solution (upper panel) and reprobed 
for RTP801 (lower panel). A representative image of three independent experiments is shown. (HMW Ub-RTP801, high molecular weight 
ubiquitinated RTP801) c. NEDD4 enhances RTP801 polyubiquitination. HEK293 cells were transfected with pHAGE or pHAGE-NEDD4 
along with HA-ubiquitin and pCMS-eGFP-RTP801 constructs. Forty-eight hours post-transfection either RTP801 was immunoprecipitated 
or non-specific rabbit immunoglobulins (Rb IgG) were added. Whole cell lysates (inputs) and the immunocomplexes were analyzed by 
Western Blot with anti-HA, anti-RTP801, anti-NEDD4 and anti-GAPDH (loading control) antibodies. A representative image of two 
independent experiments is shown. HMW Ub-RTP801 = High molecular weight ubiquitinated RTP801; IP = immunoprecipitation; IB 
= immunoblot. d. NEDD4 polyubiquitinates RTP801 with Ub-K63 chains. HEK293 cells were transfected with pCMS-eGFP-RTP801, 
along with pRK5-HA-Ub-K48 or pRK5-HA-Ub-K63 and pHAGE or pHAGE-NEDD4 as indicated. Forty-eight hours later, cultures were 
harvested and RTP801 was immunoprecipitated. Non-specific rabbit immunoglobulins (Rb IgG) were used as a negative control. Whole 
cell lysates (inputs) and RTP801 immunocomplexes were resolved in a Western Blot. Membrane was probed for HA, and reprobed for 
RTP801, for NEDD4 and for AKT as loading control. All samples were immunoblotted in the same membrane, but some irrelevant 
bands were deleted. Note the high molecular weight smears corresponding to polyubiquitinated RTP801. A representative image of three 
independent experiments is shown. IP = immunoprecipitation; IB = immunoblot.
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In conclusion, RTP801 can be subjected to 
lysosomal degradation and is conjugated with K63-linked 
polyubiquitin chains by NEDD4. 
NEDD4 and rtP801 interact in cellular models
In order to investigate whether NEDD4 and 
RTP801 interact in living cells, we overexpressed both 
NEDD4 and RTP801 in HEK293 cells. Cultures were 
incubated for 2 hours with DSP, a crosslinker agent to 
preserve weak interactions between proteins, and then 
RTP801 was immunoprecipitated. WB analysis of the 
immunocomplexes showed that ectopic RTP801 pulled 
down overexpressed NEDD4 (Figure 2a).
In order to study the complex formation in non-
transfected cells, we next investigated whether the 
endogenous NEDD4 and RTP801 interact in NGF-
differentiated PC12 cells. For this purpose, cultures were 
treated with 1 µM epoxomycin for 2 hours to abrogate 
RTP801 fast degradation and then, they were exposed to 
the crosslinker DSP for two hours more. Then, endogenous 
RTP801 was immunoprecipitated. WB analysis showed 
that NEDD4 was able to interact with endogenous RTP801 
(Figure 2b).
We next explored whether NEDD4 and RTP801 
colocalize in cultured primary neurons. We overexpressed 
HA-tagged NEDD4 in primary rat cortical cultures and we 
detected ectopic NEDD4 with an antibody against the HA 
epitope. Interestingly, endogenous RTP801 co-localized 
with HA-tagged NEDD4 in the soma and in the neurites 
(Figure 2c) of transfected neurons.
Taken together, these experiments suggest the 
physical interaction of NEDD4 and RTP801 in several 
cellular models.
NEDD4 regulates rtP801 protein levels in 
cellular models
Our next question was whether NEDD4, by 
polyubiquitinating RTP801, could regulate RTP801 
protein levels. In neuronal PC12 cells, we overexpressed 
WT NEDD4 and its inactive mutant, with the catalytic 
cysteine 867 mutated to a serine (NEDD4-C867S). After 
48 hours, cell lysates were analyzed by WB. Ectopic 
NEDD4 diminished in a 25-30% the levels of endogenous 
RTP801 protein. Interestingly, the inactive mutant form 
of NEDD4 did not affect RTP801 levels (Figure 3a). We 
obtained the same results in rat primary cortical neurons 
(Figure 3b). 
Still in cortical neurons, either ectopic NEDD4 or its 
mutant did not alter the messenger RNA levels of RTP801 
(Figure 3c). These results indicate that NEDD4 does not 
regulate the transcription of RTP801. 
We next asked whether NEDD4 knockdown 
elevates RTP801 protein levels. Therefore, in rat primary 
cortical neurons, NEDD4 expression was abrogated with 
specific shRNAs packed in lentiviruses. Six days later, 
cell lysates were analyzed by WB. Upon expression 
of shRNA for NEDD4, almost all NEDD4 protein was 
knocked down as shown in the top panel of Figure 3d. 
We observed a significant increase of RTP801 protein 
levels in the absence of NEDD4. In the same conditions, 
we also detected that the levels of phosphorylated residue 
S473 of the survival kinase Akt were diminished and the 
levels of caspase-cleaved spectrin fragment SBDP120, as 
readout of toxicity, were significantly elevated (Figure 3d). 
Thus, NEDD4 loss induces an elevation of RTP801 and is 
deleterious for cultured neurons. 
Then, we assessed whether the NEDD4 deletion 
could affect the accumulation of RTP801 in an animal 
model. NEDD4 knockout mice are not viable after birth. 
For this reason we used NEDD4f/f;Emx1Cre conditional 
knockout mice that only abolishes the expression of 
NEDD4 in glutamatergic neurons and glial cells in the 
cortex [13, 24, 25]. By WB, cortical lysates from 6-week 
old mice showed that the downregulation of NEDD4 was 
around 50%. Accordingly, RTP801 levels were increased 
by a 25% in the conditional mice in comparison to the 
control NEDD4f/f littermates (Figure 3e). 
Together, these results show that NEDD4 regulates 
protein levels of RTP801 in cultured cortical neurons and 
in vivo.
NEDD4 protects neuronal Pc12 cells from ectopic 
rtP801 toxicity
Overexpression of RTP801 induces around 50% of 
cell death in cultured neurons and non-proliferating NGF-
differentiated PC12 cells [6, 8]. With this rationale, we 
overexpressed pCMS-eGFP empty vector or with pCMS-
eGFP-RTP801 along with WT NEDD4 and the inactive 
mutant NEDD4-C867S. Twenty-four hours later, cell 
viability was assessed by scoring the number of living 
eGFP+ cells under epifluorescence microscopy. Only 
WT NEDD4 but not NEDD4-C867S protected cells from 
RTP801 toxicity (Figure 4a). Indeed, NEDD4 did not exert 
protection over non-ubiquitinable RTP801-KR mutant, 
with the 6 lysines mutated to arginines. These results 
support our notion that NEDD4 protects from RTP801 
toxicity by ubiquitinating it (Figure 4b).
PD neurotoxin 6-OHDA decreases NEDD4 and 
elevates rtP801 protein levels
In our previous works we described that 6-OHDA 
elevated RTP801 protein levels transcriptionally and 
also posttranslationally, by interfering in its proteasomal 
degradation [6, 8, 10]. We observed that in culture, 
6-OHDA was deleterious for parkin E3 ligase activity/
levels [8]. Based on this background, we next asked 
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Figure 2: NEDD4 and rtP801 interact physically. a. NEDD4 co-immunoprecipitates with rtP801 in cells exposed to 
DsP. HEK293 cells were co-transfected with empty vectors pCMS-eGFP and pCI-HA or with pCMS-eGFP-RTP801 and pCI-HA-
NEDD4. Twenty-four hours post-transfection cells were exposed to cross-linker DSP for 2 hours at 4ºC prior harvesting. RTP801 was 
immunoprecipitated and the samples were analyzed by Western Blotting. Membranes were probed with anti- NEDD4 and anti-RTP801 
antibodies. Representative images are shown of at least three independent experiments. IP = immunoprecipitation; IB = immunoblot. b. 
Endogenous RTP801 and NEDD4 interact in neuronal PC12 cells. NGF-differentiated PC12 cells were treated with 1 µM epoxomicin for 
2 hours. Then, cultures were exposed to DSP at 4 ºC for 2 hours prior harvesting. RTP801 immunocomplexes were resolved in a Western 
Blotting. The membrane was incubated with anti-NEDD4 and anti-RTP801 antibodies. A representative image is shown of at least two 
independent assays. IP = immunoprecipitation; IB = immunoblot. c. NEDD4 and RTP801 co-localize in neurons. DIV 19 primary rat 
cortical neurons were transfected with pCI-HA-NEDD4. Forty-eight hours post-transfection, neurons were fixed and stained with anti-
RTP801 (in red) and anti-HA (in green). Scale bar, 5 µm.
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Figure 3: Ectopic NEDD4 regulates rtP801 in cultured cells. a. Ectopic NEDD4 decreases rtP801 protein levels in neuronal 
Pc12 cells. NGF-differentiated PC12 cells were transfected with pCI-HA, pCI-HA-NEDD4 or pCI-HA-NEDD4-C867S constructs. Forty-
eight hours post-transfection cultures were harvested and analyzed by Western Blot with anti-NEDD4, anti-RTP801 and anti-α-actin 
antibodies. Representative immunoblots are shown along with densitometric quantification from at least three independent experiments. 
($ endogenous NEDD4, # ectopic NEDD4, * specific band for RTP801). One-way ANOVA with Bonferroni multiple comparison test, *P 
< 0.05 versus pCI-HA. b. Ectopic NEDD4 decreases RTP801 protein levels in cortical neurons. DIV 8 rat primary cortical neurons were 
infected with lentiviruses containing the empty vector pHAGE, pHAGE-NEDD4 or pHAGE-NEDD4-C867S inactive mutant. Cell lysates 
were harvested 4 days later and analyzed by Western Blot with antibodies against RTP801, NEDD4 and α-actin as loading control. The 
graph represents RTP801 densitometries of at least three independent experiments done in triplicate. One-way ANOVA with Bonferroni 
multiple comparison test, **P < 0.01 versus pHAGE. c. Ectopic NEDD4 does not affect RTP801 mRNA levels. DIV 8 cortical neurons 
were infected with lentiviruses containing the constructs pHAGE, pHAGE-NEDD4 or pHAGE-NEDD4-C867S. RNA was extracted 4 days 
later, and reverse transcription-qPCR was performed to quantify RTP801 transcripts. Results are displayed as RTP801 mRNA fold change 
respect to α-actin mRNA levels. The graph shows values (mean ± SEM) of three independent experiments. d. NEDD4 knockdown increases 
RTP801 protein levels and is detrimental for neurons. DIV 4 cortical neurons were infected with lentiviruses containing a scrambled shRNA 
(ShCt) or a mix of three shRNA sequences against NEDD4 (ShNEDD4). Six days later, cells were harvested and analyzed by Western 
Blot. Membranes were incubated with NEDD4, RTP801, P-AKT (S473), AKT and α-spectrin antibodies. The antibody against α-actin was 
used as loading control. For Western blotting using the α-spectrin antibody the caspase-cleaved fragment (spectrin breakdown product 120, 
SBDP120) is shown. Representative immunoblots are shown along with RTP801 and P-AKT (S473) densitometries (mean ± SEM) of at 
least three independent experiments. Student’s t-test, *P < 0.05 and **P < 0.01 versus ShCt. e. NEDD4f/f;Emx1Cre conditional knockout 
mice have elevated RTP801 protein levels in the cortex. Cortical lysates of 6-week old mice were analyzed by Western Blotting with anti-
NEDD4 and anti-RTP801 antibodies, and then reprobed with anti-α-actin antibody as loading control. Representative immunoblots are 
shown along with RTP801 densitometries (mean ± SEM) of at least three independent gels. All samples were immunoblotted in the same 
membrane, but some irrelevant lanes were deleted. (* Specific band for RTP801) Student’s t-test, *P < 0.05 versus WT.
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Figure 4: NEDD4 partially prevents from rtP801-induced cell death. a. Ectopic Wt NEDD4 protects from rtP801-induced 
cell death. NGF-differentiated PC12 cells were co-transfected with pCI-HA, pCI-HA-NEDD4 or pCI-HA-NEDD4-C867S constructs, 
together with either pCMS-eGFP or pCMS-eGFP-RTP801. Cells were fixed 24 hours later and cell survival (eGFP+ cells) scored under 
fluorescence microscopy. The graph represents mean ± SEM of at least three independent experiments in quadruplicates. One-way ANOVA 
with Bonferroni multiple comparison test, ***P < 0.001 versus pCI-HA/pCMS-eGFP, ##P < 0.01 versus pCI-HA/pCMS-eGFP-RTP801. 
b. NEDD4 does not protect from RTP801 KR mutant toxicity. NGF-differentiated PC12 cells were co-transfected with pCI-HA or pCI-
HA-NEDD4 together with pCMS-eGFP, pCMS-eGFP-RTP801 or pCMS-eGFP-RTP801-KR. Twenty-four hours later, cells were fixed and 
eGFP+ surviving cells scored using fluorescence microscopy. The graph represents mean ± SEM of at least three independent experiments 
in quadruplicates. One-way ANOVA with Bonferroni multiple comparison test, ***P < 0.001 versus pCI-HA/pCMS-eGFP and #P < 0.05 
versus pCI-HA/pCMS-eGFP-RTP801.
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whether 6-OHDA also influences the levels of NEDD4 
in cellular cultures. In NGF-differentiated PC12 cells, 
6-OHDA diminished NEDD4 protein levels but did not 
affect the levels of its mRNA. On the contrary, 6-OHDA 
elevated both mRNA and protein levels of RTP801 as 
reported previously (Figures 5a and 5b) [6, 8].
In order to investigate whether proteases such as 
caspases and calpains could be responsible for NEDD4 
decrease, we pre-treated NGF-differentiated PC12 cells 
for one hour with 100μM of Z-VAD-FMK, a pan caspase 
inhibitor, or with 1μM of ALLN, a calpain inhibitor, and 
then, they were exposed to 6-OHDA. Both caspase and 
calpain independent inhibition partially prevented the 
loss of NEDD4 induced by 6-OHDA. The high levels of 
caspase-cleaved (SBDP120) and calpain cleaved-spectrin 
fragments (SBDP145) confirmed the toxicity of 6-OHDA 
(Figures 5c and 5d).
Taken together, these results indicate that caspase 
and calpain activation contribute to the loss of NEDD4 
protein levels induced by 6-OHDA. 
Ectopic NEDD4 protects from 6-OHDA and 
prevents rtP801 elevation
Since 6-OHDA decreased NEDD4 protein levels 
and this could be related with the elevation of RTP801, we 
first asked whether NEDD4 restitution could be protective 
against this neurotoxin. In fact, we chose to use the 
6-OHDA model instead of over expressing alpha-synuclein 
because NEDD4 degrades alpha synuclein [15]. Thus, we 
overexpressed wild type or the inactive mutant of NEDD4 
in NGF-differentiated PC12 cells and then exposed the 
cultures to 6-OHDA. By assessing cell survival, based on 
the number of eGFP+ cells with non-condensed or non-
pyknotic nuclei (Hoechst staining), we concluded that 
ectopic WT NEDD4 partially prevented from 6-OHDA-
induced cell death while the overexpression of the mutant 
had almost no effect (Figure 6a). 
We next investigated whether the protection 
conferred by NEDD4 could be related with the modulation 
of RTP801 protein levels. WT NEDD4 or its inactive 
mutant NEDD4-C867S were overexpressed in NGF-
differentiated PC12 cells. After 32 hours, the cultures 
were exposed to 6-OHDA and cell lysates were analyzed 
by WB (Figure 6b). We observed a significant effect over 
RTP801 levels. Ectopic NEDD4 partially abrogated the 
6-OHDA-induced levels of RTP801, in comparison to 
control or the NEDD4 inactive mutant. 
Taken together, we conclude that NEDD4 protects 
from 6-OHDA toxicity and downregulates RTP801 
induced by the toxin.
NEDD4 loss is toxic due to rtP801 elevation in 
cortical neurons.
We next investigated whether the toxicity of NEDD4 
knockdown is mediated by RTP801 elevation in neurons. 
Rat primary cortical neurons were sequentially infected 
with lentiviral particles to knockdown RTP801 first and 
then NEDD4. WB analysis of the cell lysates showed 
that knocking down NEDD4 elevated RTP801 along with 
caspase-cleaved spectrin fragment SBDP120. Levels of 
phospho-S473-Akt and phospho-S6, as mTORC2 and 
mTORC1 activity readout respectively, were both reduced, 
although only P-S473-Akt was statistically significant. 
Indeed, knocking down RTP801 alone elevated the 
phosphorylation of Akt. Importantly, knocking down 
both RTP801 and NEDD4 abrogated RTP801 elevation 
and prevented the decrease of phospho-S473-Akt and 
phospho-S235/236-S6 (Figure 7). 
These results conclude that NEDD4 has a robust 
functional relationship with RTP801 in the regulation of 
downstream targets mTOR and Akt. 
NEDD4 levels are diminished in nigral neurons in 
PD brains
Previous studies showed that NEDD4 was 
upregulated in human nigral neurons containing Lewy 
Bodies (LBs) from patients diagnosed with Lewy 
bodies disease (LBD) [15]. However, only 15% of 
nigral neurons contains alpha synuclein-reactive LBs 
[26]. For this reason, we extended the study to all nigral 
neurons in SNpc sections from sporadic PD patients. We 
immunostained 6 sporadic PD and 6 control cases with a 
specific antibody for NEDD4. We scored the number of 
nigral neurons, (visualized in brown due to neuromelanin 
pigment) that were positive for NEDD4 (in blue) versus 
total nigral neurons, in each case (Figure 8). We observed, 
independently of the presence of LBs, that the percentage 
of remaining nigral neurons stained for NEDD4 was lower 
in PD cases than in the age-matched controls (Figure 
8). We did not observe staining in sections incubated 
only with the secondary antibody. This loss of NEDD4 
expression in PD correlates well with the previously 
reported RTP801 elevation in nigral neurons [6, 8].
Taken together, these results show that NEDD4 is 
decreased in nigral neurons from PD patients that could 
well explain the previously reported RTP801 elevation in 
the same neuronal population [6, 8].
DIscUssION
Here, we show that RTP801, a pro-apoptotic 
protein involved in neuron death in cellular and animal 
models of PD, is a novel substrate of NEDD4. NEDD4 
polyubiquitinates RTP801 by conjugating K63 ubiquitin 
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Figure 5: NEDD4 is decreased in a 6-OHDA PD cellular model. a. NEDD4 protein levels are diminished in 6-OHDA-
treated neuronal Pc12 cells. NGF-differentiated PC12 cells were exposed to 100 µM 6-OHDA for 16 hours prior harvesting. Cell lysates 
were analyzed by Western Blot with antibodies against NEDD4, RTP801, as well as α-actin antibody as loading control. Representative 
immunoblots are shown along with densitometries represented as mean ± SEM of at least three independent experiments. Student’s t-test, 
**P < 0.01 and ***P < 0.001 versus Ut (Untreated). b. NEDD4 mRNA levels are not modified in 6-OHDA-treated neuronal PC12 cells. 
NGF-differentiated PC12 cells were exposed to 100 µM 6-OHDA for 8 hours. RNA was extracted and reverse transcription-qPCR was 
performed. The graphs show values (mean ± SEM) of three independent experiments. Student’s t-test, ***P < 0.001 versus ut (untreated). 
c. NEDD4 is cleaved by caspases after 6-OHDA exposure. Neuronal PC12 cells were treated with 100 µM Z-VAD-FMK pan-caspase 
inhibitor for 1 hour prior to 6-OHDA exposure. Sixteen hours later, cultures were harvested and analyzed by Western Blot. Membranes 
were incubated with antibodies against NEDD4 and α-spectrin as well as an α-actin antibody as loading control. Graphs represent mean ± 
SEM of NEDD4 and caspase-cleaved α-spectrin fragment (spectrin breakdown product 120 KDa, SBDP 120) densitometric quantification 
of at least three independent experiments. One-way ANOVA with Bonferroni multiple comparison test, ***P < 0.001 versus Untreated/Ct 
and #P < 0.05, ###P < 0.001 versus 100 µM 6-OHDA/Ct. d. NEDD4 is cleaved by calpains after 6-OHDA exposure. Neuronal PC12 cells 
were treated with 1 µM ALLN calpain inhibitor for 1 hour prior to 6-OHDA exposure. Sixteen hours later, cultures were harvested and 
subjected to Western Blot. Membranes were incubated with anti-NEDD4 and anti-α-spectrin antibodies and with anti-α-actin as loading 
control. Graphs represent mean ± SEM of NEDD4 and calpain-cleaved α-spectrin fragment (spectrin breakdown product 145 KDa, SBDP 
145) densitometric quantification of at least three independent experiments. One-way ANOVA with Newman-Keuls multiple comparison 
test, **P < 0.01, ***P < 0.001 versus Untreated/Ct and #P < 0.05, ###P < 0.001 versus 100 µM 6-OHDA/Ct.
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Figure 6: NEDD4 protects from 6-OHDA-induced cell death and decreases rtP801 elevation. a. Ectopic NEDD4 WT 
partially prevents from 6-OHDA-induced cell death. NGF-differentiated PC12 cells were co-transfected with pCI-HA/pCMS-eGFP, pCI-
HA-NEDD4/pCMS-eGFP or pCI-HA-NEDD4-C867S/pCMS-eGFP vectors with a 4:1 ratio. Thirty-two hours later, cell cultures were 
exposed to 100 µM 6-OHDA for 16 hours. Then, eGFP+ surviving cells were scored under fluorescence microscopy. The graph shows mean 
± SEM of at least three independent experiments done in quadruplicate. One-way ANOVA with Bonferroni multiple comparison test, ***P 
< 0.001 versus Untreated/pCI-HA and ##P < 0.01 versus 100 µM 6-OHDA /pCI-HA. b. Ectopic NEDD4 reduces RTP801 elevation after 
6-OHDA exposure. NGF-differentiated PC12 cells were transfected with pCI-HA, pCI-HA-NEDD4 or pCI-HA-NEDD4-C867S. Thrity-
two hours later, cell cultures were exposed to 100 µM 6-OHDA for 16 hours and cell lysates were analyzed by Western Blot. Membranes 
were incubated with antibodies against NEDD4, RTP801 and α-actin as loading control (* endogenous NEDD4, # ectopic NEDD4). Low 
signal of ectopic NEDD4 maybe due low sensitivity of NEDD4 antibody towards the human NEDD4 protein, as compared to endogenous 
rat NEDD4. Representative immunoblots are shown along with RTP801 densitometric normalized quantification (mean ± SEM) from at 
least three independent experiments. One-way ANOVA with Bonferroni multiple comparison test, *P < 0.05 versus Untreated/pCI-HA, #P 
< 0.05 versus 100 µM 6-OHDA/pCI-HA.
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chains. This type of posttranslational modification is 
associated with the lysosomal pathway. NEDD4 and 
RTP801 interact physically in HEK293 and in NGF-
differentiated PC12 cells. NEDD4 also regulates RTP801 
protein levels in both cultured cells and in a conditional 
NEDD4 knockout mouse model. Moreover, NEDD4 
protein levels are diminished in remaining nigral neurons 
in human sporadic PD brains. Furthermore, we provide 
evidence that NEDD4 is protective against ectopic 
RTP801 toxicity by ubiquitinating it. We found that 
6-OHDA neurotoxin exposure decreased dramatically 
NEDD4 protein levels and its restoration abrogated 
6-OHDA-induced cell death. Ectopic NEDD4 also 
prevented RTP801 protein elevation induced by 6-OHDA. 
Finally, NEDD4 loss of function toxicity was mediated by 
RTP801 by inactivating mTOR/Akt kinases.
The finding that RTP801 is also degraded by the 
lysosomal system in neurons was yet not known. In 
lymphocytes treated with dexamethasone, RTP801/
REDD1 mediated the fusion of lysosomes with 
autophagosomes, and therefore it mediated autophagy 
[27]. Interestingly, mTORC1 translocates to the lysosomes 
surface via the Rag-ragulator complex to be activated [28]. 
One can speculate that NEDD4 targeting RTP801 to the 
lysosomal degradation pathway is necessary for lysosomal 
mTOR translocation/activation; therefore an elevation of 
RTP801 could be deleterious for this process. 
Our previous studies confirmed that RTP801 was 
mostly degraded by the proteasome. This is in line with the 
evidence relating proteins with short half-lives more prone 
to be degraded by the proteasome. However, here we 
found a pool of RTP801 that is degraded by the lysosomal 
pathway. Both proteasome and lysosome systems seem to 
be impaired in PD [29, 30]. Thus, based on our previous 
and current results, the deregulation of both processes 
could be contributing importantly to RTP801 elevation in 
the pathogenesis of PD. 
We show that NEDD4 ubiquitinates RTP801, 
preferentially with K63-ubiquitin chains. K63-ubiquitin 
chains have a low affinity for the 26S proteasome 
subunit and they rather bind other soluble proteins, such 
as ESCRT-0 (Endosomal Sorting Complex Required 
for Transport) and its components, STAM and Hrs that 
block the interaction with S26 proteasomal subunit [31]. 
Therefore they are targeted to the lysosomal pathway. 
On the contrary, K48-ubiquitin chains have more affinity 
for Rad23 proteins, especially hHR23B, that promote 
proteasome binding [31].
NEDD4 binds proteins with proline rich motifs [32] 
or phospho-serines or phospho-threonines [33] via its WW 
binding domains. Indeed, RTP801 protein sequence has a 
proline rich region in the fragment close to the N-terminus 
that contains several serines and threonines. Interestingly, 
threonine residues 23 and 25 fit the consensus sequence 
for GSK3b kinase and could be therefore, phosphorylated 
[34]. 
To date only three E3 ligases have been described 
to regulate RTP801: CUL4A- DDB1-ROC1-b-TRCP 
E3 ligase complex, HUWE-1 and parkin. CUL4A-DDB 
polyubiquitinates RTP801 and mediates its proteasomal 
degradation in a GSK3 phosphorylation dependent 
manner [34]. However, other authors could not confirm 
these results by using a chemical inhibitor of all cullin E3 
ligases [35]. 
We recently found that parkin polyubiquitinates 
RTP801 and mediates its proteasomal degradation [8]. 
Parkin dysfunction, due to mutations or oxidative/
nitrosative stress has been consistently linked to PD [36-
40]. Regarding NEDD4 involvement in PD, Tofaris and 
colleagues (2011) [15] first described the possible role of 
NEDD4 in the endosomal-lysosomal degradation of alpha-
synuclein in cellular models and in yeast. However in their 
work, whether NEDD4 activity was altered in PD, as it is 
the case with parkin, was not clear. 
NEDD4 knockdown elevated RTP801 and caspase-
cleaved spectrin fragment SBDP120. Interestingly it also 
inactivated Akt by decreasing the levels of phosphorylation 
at the Serine-473 residue. All these events suggest that 
NEDD4 loss of function was toxic for neurons.
These signaling events were clearly observed 
in mature rat cortical neurons although they were not 
significant in the 6-week-old mice cortical lysates from the 
NEDD4f/f;Emx1Cre conditional knock out mice. These 
results suggest that in these mice, neuronal death could be 
masked due to compensatory mechanisms. 
NEDD4 loss is toxic in cortical neurons and at 
least, it involves RTP801 elevation and inactivation of the 
mTOR/Akt kinases. In fact, knocking down RTP801 at the 
same time as NEDD4 prevented the loss of phospho-Akt 
and phospho-S6 and the appearance of caspase-cleaved 
spectrin fragments. NEDD4 has been related with Akt 
survival signaling. NEDD4 polyubiquitinates phospho-
Akt at the plasma membrane to modulate Akt subcellular 
localization [41]; it binds to GRB10 to regulate IGF-1 and 
insulin signaling, including IGF1 receptor ubiquitination 
[42]. Interestingly, Grb10 is an mTORC1 substrate [43]. 
Hence, NEDD4 activity over RTP801, which in turn 
is a negative regulator of Akt and mTOR, would be crucial 
to prevent neurodegeneration.
Consistent with the toxicity induced by the loss of 
NEDD4 in cultured cells, we found in human PD brains 
that the percentage of NEDD4-stained nigral neurons were 
lower in PD cases than in age-matched controls. This 
result correlates with the previously reported elevation 
of RTP801 in nigral neurons in sporadic PD cases [6, 8]. 
However, Tofaris et al. (2011) [15] described that NEDD4 
was strongly expressed in pigmented neurons from both 
LC and SN containing LBs, as a neuroprotectective 
mechanism against neurodegeneration [15]. According 
to literature, only 15% of the remaining nigral neurons 
contains LB [26]. The fact that we considered all the 
remaining nigral neurons could explain the differences 
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Figure 7: NEDD4 knockdown toxicity is dependent on rtP801 protein. DIV 5 primary rat cortical neurons were infected with 
lentiviruses containing a scrambled shRNA (ShCt) or a shRNA against RTP801 (ShRTP801). Two days later, neurons were transduced 
with a mix of three shRNA sequences against NEDD4 (ShNEDD4) or the corresponding control shRNA (ShCt). Cell lysates were analyzed 
4 days later by Western Blot. Membranes were incubated with RTP801, NEDD4, P-AKT (S473), AKT, P-S6 (S235/236), ERK1/2 and 
α-spectrin antibodies, and with α-actin antibody as loading control. For α-spectrin the caspase-cleaved fragment (spectrin breakdown 
product 120, SBDP120) is shown. Representative immunoblots are shown along with densitometries (mean ± SEM) of at least two 
independent experiments done in triplicate. One-way ANOVA with Newman-Keuls multiple comparison test, *P < 0.05, **P < 0.01 versus 
ShCt/ShCt and #P < 0.05, ##P < 0.01 versus ShCt/ShNEDD4. 
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Figure 8: NEDD4 is decreased in pigmented nigral neurons from sporadic PD patients. SNpc human postmortem sections 
from control individuals (CT1-CT6) and sporadic PD patients (SPD1-SPD6) were immunostained for NEDD4 (grey-blue). Note the 
presence of neuromelanin (NM) granules (brown) within the somas of dopaminergic neurons. Neuromelanin-positive (NM+) neurons were 
scored positive for NEDD4 when detectable staining was observed. For each case, the percentage of NM+ and NEDD4+ neurons versus 
total NM+ neurons was represented in the graph. A control section was immunostained with no primary antibody as negative control. 
Arrows indicate some of the positive cells stained for NEDD4 and asterisks show some of the negative cells for NEDD4. Counting was 
performed in blind conditions. Student’s t-test, *P < 0.05.
Oncotarget58826www.impactjournals.com/oncotarget
between these two works. Whether RTP801 is elevated in 
LC has not been yet explored.
In conclusion, here we show that the HECT E3 
ligase NEDD4 mediates the ubiquitination of proapoptotic 
protein RTP801 and its lysosomal degradation. We 
observed that NEDD4 knockdown is toxic for neurons 
and this toxicity is counteracted when RTP801 elevation 
is abrogated. Moreover, the levels of NEDD4 in the 
remaining nigral neurons in human PD brains are 
diminished. These nigral neurons also present elevated 
levels of RTP801. Thus, the loss of NEDD4 in PD could 
be leading to neurodegeneration at least in part, by 
contributing to RTP801 toxic accumulation.
mAtErIALs AND mEtHODs
Antibodies, plasmids and materials
Rabbit polyclonal antibody against RTP801 was 
purchased from Proteintech Group Inc (Chicago, IL, 
USA). Rabbit polyclonal anti-NEDD4 (used for WB), 
rabbit polyclonal anti-ERK1/2 and mouse monoclonal 
anti-GFP antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). Anti-HA antibody 
(used for WB), anti-P-Akt (S473), anti-P-S6 (S235/236) 
and anti-Akt rabbit polyclonal antibody were purchased 
from Cell Signaling Technology (Danvers, MA, USA). 
Mouse monoclonal antibody against HA-tag (used for 
immunofluorescence) was obtained from Sigma-Aldrich 
(Sant Louis, MO, USA). Ubiquitin (FK2) antibody was 
purchased from Enzo Life Sciences (Farmingdale, NY, 
USA). Rabbit polyclonal antibody against NEDD4 and 
GAPDH (used for immunohistochemistry) were from 
Abcam (Cambridge, UK). The antibody against αII-
spectrin was purchased from Merck Millipore (Billerica, 
MA, USA). Anti-α-actin antibody was obtained from 
MP Biomedicals (Santa Ana, CA, USA). Horseradish 
peroxidase-conjugated goat anti-mouse and anti-rabbit 
secondary antibodies were obtained from Pierce Thermo 
Fisher Scientific (Rockford, IL, USA). Goat anti-mouse 
and anti-rabbit secondary antibodies conjugated to Alexa 
488 or Alexa 568 were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA).
pCMS-eGFP-RTP801 and pCMS-eGFP-RTP801 
KR constructs were generated as previously described 
[6, 8]. pCI-HA-NEDD4 and pcDNA3 HA-ubiquitin were 
purchased from Addgene (Cambridge, MA, USA). The 
construct pCI-HA was a kind gift from Dr. Joan Massagué 
(Memorial Sloan Kettering Cancer Center, New York, 
NY, USA). pHAGE and pHAGE-NEDD4 constructs were 
kindly provided by Dr.Heng-Ye Man (Boston University, 
MA, USA). pRK5-HA-ubiquitin-K48 and pRK5-HA-
ubiquitin-K63 were a kind gift from Dr. Bernat Crosas 
(Molecular Biology Institute of Barcelona, CSIC, Spain). 
The lentivirus packaging plasmids pMDLg/pRRE, 
pRSV-Rev and pMD2.G used to knockdown RTP801 
were obtained from Addgene. The lentivirus packaging 
plasmids pHDM-Tat1b, pRC/CMV-Rev1b, pHDM-
Hgpm2 and pHDM-G used to overexpress NEDD4 were 
kindly provided by Dr. Heng-Ye Man. All vectors were 
validated by DNA sequencing. 
Epoxomicin, MG132, cycloheximide, Z-VAD-
FMK, and ALLN were purchased from Calbiochem Merck 
Millipore (Billerica, MA, USA), chloroquine and CHAPS 
were obtained from Sigma-Aldrich, and 6-OHDA was 
purchased from Tocris Bioscience (Bristol, UK).
Directed mutagenesis
pCI-HA-NEDD4-C867S and pHAGE-NEDD4-
C867S constructs were obtained by mutating the 
catalytic cysteine (C) 867 to serine (S) of pCI-
HA-NEDD4 and pHAGE-NEDD4 vectors. The 
QuickChange Lightning II multi site-directed 
mutagenesis kit (Agilent Technologies, Santa Clara, 
CA, USA) was used with the following primer: 5’-GTC 
CAGGCGATTAAAACTGGTATGAGCTCTTGGCA-3’. 
All new constructs were validated by DNA sequencing.
shrNA production
Scrambled control ShRNA (ShCt) and 
ShRTP801 were generated as previously described 
[6], based on the following sequences: ShCt, 5’- 
GTGCGTTGCTAGTACCAAC-3’, ShRTP801, 
5’-AAGACTCCTCATACCTGGATG-3’ (specific for 
human, rat and mouse RTP801). The two ShRNA were 
inserted into the lentiviral vector pLL3.7 (Addgene). 
NEDD4f/f;Emx1Cre mice
In order to generate the forebrain specific NEDD4 
conditional knockout mouse, Nedd4f/f mice [13] were 
crossed with Emx1Cre mouse [24]. Emx1Cre mice express 
Cre recombinase in the radial glia cells, resulting in flox-
recombination of floxed target genes in glutamatergic 
neurons and glia cells in the cerebral cortex. 
cell culture
PC12 cells were maintained and differentiated with 
NGF as previously described [18]. For NGF treatment, 
cells were grown in RPMI 1640 medium (Thermo Fisher 
Scientific) supplemented with 1% heat-inactivated horse 
serum (Sigma-Aldrich), penicillin/streptomycin (Thermo 
Fisher Scientific) and 50 ng/ml recombinant human 
β-NGF (Alomone Labs, Jerusalem, Israel) for 7-8 days in 
a 7,5% CO
2
 atmosphere at 37ºC. Medium was changed 
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every other day and before transfection.
HEK293 cells were cultured in DMEM medium 
supplemented with 10% fetal bovine serum and penicillin/
streptomycin (all from Thermo Fisher Scientific) in a 5% 
CO
2
 atmosphere at 37ºC.
Rat primary cortical cultures were prepared as 
previously reported [19]. Briefly, cortex from embryonic 
(E18) Sprague-Dawley rats were dissected out, dissociated 
and plated at a density of 250 cells/mm2 on poly-L-lysine-
coated (Sigma-Aldrich) coverslips or at a density of 700 
cells/mm2 on poly-L-lysine-coated plates. Neurons were 
maintained in neurobasal medium with B27 and 2mM 
GlutaMAX (all from Gibco). However, neurons plated 
on coverslips were initially seeded with MEM medium 
supplemented with 100 mM pyruvic acid (Gibco), 20% 
glucose (Sigma-Aldrich) and 10% heat-inactivated horse 
serum.
Lentiviral preparation
Lentiviral particles were produced by transient 
transfection with Lipofectamine 2000 (Thermo 
Fisher Scientific) in HEK293 cells. 72 hours post-
transfection, cell medium was collected, centrifuged to 
remove debris and filtered through 0.45 µm-pore filters 
(Thermo Scientific). Lentiviruses were concentrated by 
ultracentrifugation and resuspended in sterile PBS Ca2+/
Mg2+ (Fisher Scientific). Viral titer was assessed by 
transduction of several viral dilutions.
transfection, treatments and viral infection
Primary rat cortical neurons, neuronal PC12 cells 
or HEK293 cells were transfected with Lipofectamine 
2000 (Thermo Fisher Scientific) in accordance with 
the manufacturer’s instructions. Neuronal PC12 cells 
transfection rate is around 15-20% and % of neuronal viral 
transduction is at least a 60%.
6-OHDA treatments were performed after 5-6 days 
of differentiation in NGF-treated PC12 cells. Medium was 
replaced right before exposure to the toxin. 
Rat cortical neurons were infected at DIV 4 or at 
DIV 7 with lentiviral particles containing an ShRNA 
construct against rat NEDD4 (ShNEDD4) or a scrambled 
control sequence (ShCt), both purchased from Santa 
Cruz Biotechnologies. In the case of lentiviral particles 
containing ShCt and ShRTP801, cortical neurons were 
transduced at DIV 5. Lentiviral particles containing 
pHAGE, pHAGE-NEDD4 or pHAGE-NEDD4-C867S 
were infected at DIV 7. In all cases, neurons were infected 
at a multiplicity of infection (MOI) of 1.
In vitro ubiquitination assay
The Ubiquitinylation Kit (Enzo Life Sciences) was 
used to perform the assay. Manufacturer’s instructions 
were followed with minor modifications. Shortly, 1 
mM dithiothreitol in 20 mM Tris-HCl pH 7.5, 20 U/
ml inorganic pyrophosphatase, 5 mM Mg-ATP, 2,5 µM 
biotinylated ubiquitin, 0,1 µM His6-tagged recombinant 
human ubiquitin-activating enzyme E1, His6-tagged 
recombinant human ubiquitin-conjugating enzyme 
UbcH5b E2 (Enzo Life Sciences), recombinant human 
NEDD4 protein (Sigma Aldrich) and N-terminal GST-
tagged recombinant human RTP801 full-length protein 
(Novus Biologicals, Littleton, CO, USA) were added to 
the reaction buffer, as specified in each condition, and 
then incubated at 37ºC for 90 min. Next, RTP801 was 
immunoprecipitated using an anti-RTP801 antibody and 
equal volumes of each sample were analyzed by WB. 
Membranes were probed for biotinylated ubiquitin using 
Avidin/Biotin-Horseradish Peroxidase (Ultra-sensitive 
ABC staining kit; Thermo Fisher Scientific) or for 
RTP801.
Western blot
Whole cell extracts and NEDD4f/f;Emx1Cre cortical 
lysates were collected and processed as previously 
described [6, 44]. Chemiluminiscent images were acquired 
using a LAS-3000 Imager (Fujifilm, Valhalla, NY, USA) 
and quantified by computer-assisted densitometric analysis 
(ImageJ).
Immunoprecipitation and ubiquitination assay
Cell extracts were collected with RIPA buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 (Sigma-
Aldrich), 1% sodium deoxycholate (Sigma-Aldrich) and 
0.1% sodium dodecyl sulfate (Sigma-Aldrich), containing 
mini cOmplete protease inhibitor (Roche Diagnostics 
Corporation, Indianapolis, IN, USA). Lysates were further 
solubilized by sonication and centrifuged for 10 min at 
13000 g to remove insolubilities. Equal amounts of total 
protein were incubated overnight (O/N) on rotation at 4ºC 
with protein A-agarose beads (Santa Cruz Biotechnology) 
and with the corresponding antibody or a normal 
immunoglobulin (Santa Cruz Biotechnology) as a negative 
control. Then the beads were centrifuged and washed four 
times with RIPA buffer and the immunocomplexes were 
collected and analyzed by WB.
co-immunoprecipitation
The cross-linking agent DSP (Thermo Fisher 
Scientific) was applied to cell cultures according 
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to manufacturer’s instructions. Then, cell extracts 
were collected with cell lysis buffer (Cell Signaling 
Technology). Equal amounts of total protein were 
incubated overnight (O/N) at 4ºC on rotation with protein 
A-agarose beads (Santa Cruz Biotechnology) and with 
RTP801 antibody or a normal immunoglobulin (Santa 
Cruz Biotechnology). Beads were centrifuged, washed 
four times with CHAPS buffer (Tris 50 mM pH 7.4, 
NaCl 150 mM, MgCl
2
 10 mM, CHAPS 0,4%), and the 
immunocomplexes were resolved in a WB. 
Quantitative reverse transcription-Pcr
Total RNA was isolated from NGF-differentiated 
PC12 cells or rat primary cortical neurons with the 
High Pure RNA Isolation Kit (Roche Diagnostics 
Corporation, Indianapolis, IN, USA). cDNA reverse 
transcription from total RNA was performed by using 
the Transcriptor First Strand cDNA synthesis Kit (Roche 
Diagnostics Corporation). The following primers were 
used for quantitative PCR amplification: RTP801 forward 
primer, 5’-GCTCTGGACCCCAGTCTAGT-3’; RTP801 
reverse primer, 5’-GGGACAGTCCTTCAGTCCTT-3’; 
NEDD4 forward primer, 5’- 
GGACGAGGTATGGGAGTTCT-3’; NEDD4 reverse 
primer, 5’- CTCCACTCATCGGGTCATAC-3’; α-actin 
forward primer, 5’-GGGTATGGGTCAGAAGGACT-3’; 
and α-actin reverse primer, 
5’-GAGGCATACAGGGACAACAC-3’. Quantitative 
PCR was carried out with a 7500 Real Time PCR System 
(Applied Biosystems, Foster City, CA, USA) using equal 
amounts of cDNA template. Quantitative PCR analysis 
of RTP801 or NEDD4 was normalized by α-actin and 
analyzed using the comparative quantification.
Immunofluorescence
NGF-differentiated PC12 cells and rat primary 
cortical neurons were fixed with 4% paraformaldehyde 
in PBS and stained as previously described [7]. Cortical 
neurons were permeabilized with PBS containing 
0.25% Triton X-100 during 5 minutes, and blocked with 
superblock-PBS for 30 minutes. In cell survival assays, 
transfected viable cells were scored by strip counting [6]. 
Immunohistochemistry of human sections
Postmortem human SNpc paraffin-embedded 
sections from sporadic PD patients and control 
individuals were obtained from the Neurological Tissue 
Bank (Biobank-HC-IDIBAPS) and stained as previously 
reported [6]. Sections were dewaxed with xylene and 
rehydrated by incubation in ethanol series (100%, 95%, 
70% and 50%). Antigen retrieval was performed with Tris-
EDTA buffer (10 mM Tris-base pH = 9, 1 mM EDTA, 
0.05% Tween 20) in a vegetable steamer at 100ºC for 20 
minutes. Then, slides were blocked in superblock-PBS 
for 2 hours at room temperature and were incubated with 
avidin/biotin solution (Vector Laboratories, Burlingame, 
CA). Sections were incubated O/N at 4ºC with anti-
NEDD4 antibody (Abcam), washed with TBS-0.025% 
Triton X-100 and incubated for 15 minutes with 0.3% H
2
O
2
 
table 1: Human brain samples information. 
PAtIENt 
ID
cLINIcAL 
DIAGNOsIs
ANAtOmO-PAtHOLOGIcAL 
DIAGNOsIs GENDEr AGE
tImE 
POstmOrtEm
(hours)
CT1 Control NFT II + alpha synuclein in olfactory bulb Male 64 10
CT2 Control AgD I Male 83 13
CT3 Control Cerebral metastasis from lung cancer + NFTI-II Female 56 14
CT4 Control Spine thrombosis D + cerebellar ictus +bulb, NFT III Female 86 4
CT5 Control iLBD Braak 1, NFT I-II, SVD Male 78 6
CT6 Control Minimum AgD I, with patched gliosis Male 76 11,5
SPD1 PD LBD Braak 4, ARP I B Male 71 5
SPD2 PD LBD Braak 4  + NFT Braak II Male 77 12
SPD3 PD LBD Braak 4, ARP II/A, discreet CAA, SVD Male 88 15
SPD4 PD LBD 4-5 + ARP IIA Female 83 4
SPD5 PD LBD Braak 5 + ARP III B + CAA mod Male 74 8
SPD6 PD LBD Braak 5 + AgD Male 81 5
CT= control individuals, SPD= sporadic PD patients LBD: Lewy body disease, stages based on Braak et al. (2003): 1-6. 
ARP: Alzheimer-type pathology:  classification of the neurofibrillary pathology NFT based on Braak et al., (2006) (I-VI) and 
the neuritic plaques based on CERAD criteria (A-C), CAA amyloid angiopathy. PMD: postmortem delay (in hours). AgD: 
Argyrophilic grain Disease, SVD Small Vessel Disease.
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in TBS. Secondary antibody incubation was performed for 
2 hours at room temperature with biotinylated goat anti-
rabbit secondary antibody (Vector Laboratories). Finally, 
slides were incubated with ABC Peroxidase Standard 
Staining Kit (Thermo Fisher Scientific) for 30 minutes 
and with ImmPACT SG Peroxidase Substrate (Vector 
Laboratories) for 20 minutes. Sections were washed, 
dehydrated by incubation in ethanol series (50%, 70%, 
95% and 100%) and xylene, mounted with DPX mountant 
(Sigma-Aldrich) and examined under the microscope.
statistics
All experiments were performed at least in triplicate 
and results are expressed as the mean ± SEM. Statistical 
analyses were performed with unpaired Student’s t test or 
when comparing multiple groups with one-way ANOVA 
with Bonferroni or Newman-Keuls multiple comparison 
test, as indicated in figure legends. Values of P < 0.05 were 
considered as statistically significant.
Abbreviations
6-OHDA, 6-hydroxydopamine; DSP, dithiobis 
succinimidyl propionate; eGFP, enhanced green 
fluorescent protein; HMW, high molecular weight; 
IB: immunoblot; IP, immunoprecipitation; mTOR, 
mechanistic target of rapamycin; NEDD4, neural precursor 
cell expressed developmentally down-regulated protein 4; 
NGF, nerve growth factor; NM+, neuromelanin positive; 
PD, Parkinson’s disease; shRNA, short hairpin RNA; 
SPD, sporadic Parkinson’s disease; SNpc, substantia 
nigra pars compacta; UPS, ubiquitin proteasome system; 
WB, western immunoblotting; WT, wild-type; SNP, single 
nucleotide polymorphism.
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